---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-23-056503"
form_type: "8-K"
ticker: "GYRE"
cik: "0001124105"
company_name: "GYRE THERAPEUTICS, INC."
filed_at: "2023-12-06T23:59:59+00:00"
generated_at: "2026-06-07T16:50:17.189043+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# GNI Japan revises FY2023 profit forecast up ¥6.97B on conversion of Gyre preferred stock

## Summary
- GNI Japan recognized ¥8,873M other income from converting Gyre Series X Preferred into 8,767,333 common shares.
- Revised FY2023 operating profit forecast ¥15,744M (up 116% from ¥7,280M); profit attributable to owners ¥8,971M (up 347%).
- Revised EPS forecast ¥180.42 vs previous ¥42.20; prior year ¥8.19.
- Conversion based on $0.51/share closing price of CBIO on Oct 30, 2023; shares to be issued Jan 22, 2024.
- Forecast excludes mark-to-market of Gyre common stock; further discussions ongoing.

## SEC filing metadata
- accession: 0001140361-23-056503
- form_type: 8-K
- ticker: GYRE
- cik: 0001124105
- company_name: GYRE THERAPEUTICS, INC.
- filed_at: 2023-12-06T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1124105/000114036123056503/0001140361-23-056503-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1124105/000114036123056503/ef20016120_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-23-056503
- JSON: https://secwatch.observer/filing/0001140361-23-056503.json
- Plain text: https://secwatch.observer/filing/0001140361-23-056503.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.